Styryl sulfone anticancer agents

Details Styryl sulfone anticancer agents Styryl sulfone anticancer agents

2000-03-24

2002-03-19

Vollano, Jean F. (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Sulfur, selenium or tellurium compound

C514S709000, C568S034000

Reexamination Certificate

active

06359013

ABSTRACT:

FIELD OF THE INVENTION
The invention relates to compositions and methods for the treatment of cancer, in particular breast and prostate cancer.
BACKGROUND OF THE INVENTION
Extracellular signals received at transmembrane receptors are relayed into the cells by the signal transduction pathways (Pelech et al.,
Science
257:1335 (1992)) which have been implicated in a wide array of physiological processes such as induction of cell proliferation, differentiation or apoptosis (Davis et al.,
J. Biol. Chem
. 268:14553 (1993)). The Mitogen Activated Protein Kinase (MAPK) cascade is a major signaling system by which cells transduce extracellular cues into intracellular responses (Nishida et al.,
Trends Biochem. Sci
. 18:128 (1993): Blumer et al.,
Trends Biochem. Sci
. 19:236 (1994)). Many steps of this cascade are conserved, and homologous for MAP kinases have been discovered in different species.
In mammalian cells, the Extracellular-Signal-Regulated Kinases (ERKs), ERK-1 and ERK-2 are the archetypal and best-studied members of the MAPK family, which all have the unique feature of being activated by phosphorylation on threonine and tyrosine residues by an upstream dual specificity kinase (Posada et al.,
Science
255:212 (1992); Biggs III et al.,
Proc. Natl. Acad. Sci. USA
89:6295 (1992); Garner et al.,
Genes Dev
. 6:1280 (1992)).
Recent studies have identified an additional subgroup of MAPKs, known as c-Jun NH2-terminal kinases 1 and 2 (JNK-1 and JNK-2), that have different substrate specificities and are regulated by different stimuli (Hibi et al.,
Genes Dev
. 7:2135 (1993)). JNKs are members of the class of stress-activated protein kinases (SPKs). JNKs have been shown to be activated by treatment of cells with UV radiation, pro-inflammatory cytokines and environmental stress (Derijard et al.,
Cell
1025 (1994)). The activated JNK binds to the amino terminus of the c-Jun protein and increases the protein's transcriptional activity by phosphorylating it at ser63 and ser73 (Adler et al.,
Proc. Natl. Acad. Sci. USA
89:5341 (1992); Kwok et al.,
Nature
370:223 (1994)).
Analysis of the deduced primary sequence of the JNKs indicates that they are distantly related to ERKs (Davis,
Trends Biochem. Sci
. 19:470 (1994)). Both ERKs and JNKs are phosphorylated on Tyr and Thr in response to external stimuli resulting in their activation (Davis,
Trends Biochem. Sci
. 19:470 (1994)). The phosphorylation (Thr and Tyr) sites. Which play a critical role in their activation are conserved between ERKs and JNKs (Davis,
Trends Biochem
, 77
. Sci
. 19:470 (1 994)). However, these sites of phosphorylation are located within distinct dual phosphorylation motifs: Thr-Pro-Tyr (JNK) and Thr-Glu-Tyr (ERK). Phosphorylation of MAPKs and JNKs by an external signal often involves the activation of protein tyrosine kinases (PTKs) (Gille et al.,
Nature
358:414 (1992)). which constitute a large family of proteins encompassing several growth factor receptors and other signal transducing molecules.
Protein tyrosine kinases are enzymes which catalyze a well defined chemical reaction: the phosphorylation of a tyrosine residue (Hunter et al.,
Annu Rev, Biochem
54:897(1985)). Receptor tyrosine kinases in particular are attractive targets for drug design since blockers for the substrate domain of these kinases is likely to yield an effective and selective antiproliferative agent. The potential use of protein tyrosine kinase blockers as antiproliferative assents was recognized as early as 1981. when quercetin was suggested as a PTK blocker (Graziani et al.,
Eur. J. Biochem
. 135:583-589 (1983)).
The best understood MAPK pathway involves extracellular signal-regulated kinases which constitute the Ras/Raf/MEK/ERK kinase cascade (Boudewijn et al.,
Trends Biochem. Sci
. 20, 18 (1995)). Once this pathway is activated by different stimuli, MAPK phosphorylates a variety of proteins including several transcription factors which translocate into the nucleus and activate gene transcription. Negative regulation of this pathway could arrest the cascade of these events.
What are needed are new anticancer chemotherapeutic agents which target receptor tyrosine kinases and which arrest the Ras/Raf/MEK/ERK kinase cascade. Oncoproteins in general, and signal transducing proteins in particular, are likely to be more selective targets for chemotherapy because they represent a subclass of proteins whose activities are essential for cell proliferation, and because their activities are greatly amplified in proliferative diseases.
SUMMARY OF THE INVENTION
According to one embodiment of the invention, novel compounds are provided according to formula I:
wherein
R
1
and R
2
are independently selected from the group consisting of chlorine, fluorine and bromine; and
R
3
is selected from the group consisting of hydrogen and fluorine;
R
1
and R
2
may not both be chlorine when R
3
is hydrogen: and
R
1
may not be chlorine when R
2
is fluorine and R
3
is hydrogen in the same compound.
According to another embodiment of the invention a pharmaceutical composition is provided comprising a pharmaceutically acceptable carrier and a compound of formula II
wherein
n is zero or one;
R
1
is selected from the group consisting of hydrogen, chlorine, fluorine and bromine;
R
2
is selected from he group consisting of hydrogen, chlorine, fluorine, bromine, methyl and methoxy; and
R
3
is selected from the group consisting of hydrogen, chlorine and fluorine; provided,
R
2
may not be methyl or methoxy when R
1
and R
3
are both hydrogen and n is zero or one; and
R
1
, R
2
and R
3
may not all be hydrogen when n is one.
According to a preferred embodiment, the pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound of the formula II, wherein R
3
is hydrogen, and R
1
and R
2
are independently selected from the group consisting of chlorine, fluorine and bromine.
According to another embodiment of the invention, a pharmaceutical composition is provided comprising a pharmaceutically acceptable carrier and a compound of the formula III
wherein
R
1
is selected from the group consisting of hydrogen, chlorine, fluorine and bromine.
According to another embodiment of the invention, a method of treating an individual for breast or prostate cancer is provided, comprising administering to said individual an effective amount of a compound according to formula II or formula III, alone or in combination with a pharmaceutically acceptable carrier. In another embodiment, a method of inhibiting growth of breast or prostate tumor cells in an individual afflicted with breast or prostate cancer is provided, comprising administering to said individual an effective amount of a compound according to formula III, alone or in combination with a pharmaceutically acceptable carrier. Furthermore, a method of inducing apoptosis of breast or prostate tumor cells in an individual afflicted with breast or prostate cancer is provided comprising administering to said individual an effective amount of a compound according to formula III, alone or in combination with a pharmaceutically acceptable carrier.
The invention also relates to a pharmaceutical composition and therapeutic methods as described above, wherein the compound is of the formula IV:
wherein
R
1
is selected from the group consisting of fluorine and bromine, and R
2
is selected from the group consisting of 2-chlorophenyl, 4-chlorophenyl, 4-fluorophenyl and 4-nitro.


REFERENCES:
patent: 2532612 (1950-12-01), Doumani
patent: 3185743 (1965-05-01), Combe et al.
patent: 3418101 (1968-12-01), Buchholtz et al.
patent: 3514386 (1970-05-01), Oswald et al.
patent: 3917714 (1975-11-01), Richmond
patent: 4161407 (1979-07-01), Campbell
patent: 4386221 (1983-05-01), Hyatt et al.
patent: 4937388 (1990-06-01), Bushell et al.
patent: 5659087 (1997-08-01), Aikins et al.
CA:76:121420 abs of Brit. J. Dermatol. Suppl by Findlay et al No. 7 pp 44-9, 1971.*
CA:105:133446 abs of Proc Indian Acad Sci Chem Sci by Naidu et al 95(4) pp 391-5, 1985.*
CA:122:160195 abs of correction in ACH Mode

Affiliated with

Also associated with

Rating

Styryl sulfone anticancer agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Styryl sulfone anticancer agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Styryl sulfone anticancer agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2826966